~~<i id='E5F7660527'><strike id='E5F7660527'><tt id='E5F7660527'><pre id='E5F7660527'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

fashion

author：Wikipedia 2025-10-01 21:34:49 - browse：7

The FDA has taken a big step in encouraging drug companies to include pregnant women in clinical trials, issuing a draft guidance outlining how to do so safely and ethically.

Nearly 4 million women in the U.S. give birth each year, but few drugs have been approved as safe and effective to use during pregnancy. The new guidance aims to help drug companies address those information gaps “through judicious inclusion of pregnant women in clinical trials and careful attention to potential fetal risk.”

Experts say it’s a sign of progress on an issue that’s long plagued pregnant women and their physicians.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： With Roe v Wade overturned, abortion providers work to adapt

focus

entertainment

hotspot

explore

knowledge

hotspot

AdobeThinkingaboutmessagingyourphysicianaboutaweirdrash?Youmaywanttoholdoffonit.Somehospitalsystemsh

WSS

Some top drug companies are starting to take action on climate

Change Healthcare cyberattack prompts Medicare loan program

What will Novo Nordisk's VC do with its influx of cash?

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

Just how do doctors, lawmakers, and the public define abortion?

Former medical device CEO who sold dummy, plastic parts convicted of fraud

focus

fashion

focus

Virginia high school admissions case could be legal follow

NEJM study link tiny plastics in blood vessels to heart problems

At least 13 dead in Texas as scorching temps continue

RSV shot was 90% effective at preventing hospitalizations in kids

Dobbs anniversary: the lost opportunity of abortion as health care

Former medical device CEO who sold dummy, plastic parts convicted of fraud

Drug repurposing or repositioning? The language matters

The problem with charging patients to message their doctors

Medical leaders decry Supreme Court decision on affirmative action

IVG is promising — but it won’t replace IVF quite yet

entertainment

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

Congress extends some pandemic preparedness programs

A deep dive into Applied Therapeutics’ data, and questions on Cassava

The problem with charging patients to message their doctors

What will Novo Nordisk's VC do with its influx of cash?

hotspot

explore

knowledge

hotspot